Sanofi Price to Sales Ratio 2010-2023 | SNY

Historical PS ratio values for Sanofi (SNY) over the last 10 years. The current P/S ratio for Sanofi as of April 19, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Sanofi P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-04-19 46.30 2.31
2023-12-31 49.73 $20.07 2.48
2023-09-30 53.64 $19.56 2.74
2023-06-30 53.90 $18.56 2.90
2023-03-31 52.44 $19.00 2.76
2022-12-31 46.67 $14.33 3.26
2022-03-31 47.88 $13.89 3.45
2021-09-30 44.96 $13.98 3.22
2021-06-30 49.11 $12.99 3.78
2021-03-31 44.44 $17.40 2.55
2020-09-30 45.08 $17.07 2.64
2020-03-31 37.91 $16.47 2.30
2019-09-30 40.17 $16.54 2.43
2019-03-31 36.85 $16.54 2.23
2018-03-31 31.84 $16.48 1.93
2017-12-31 34.16 $16.23 2.10
2017-09-30 39.55 $15.88 2.49
2017-06-30 38.06 $15.51 2.45
2017-03-31 34.77 $15.25 2.28
2016-12-31 31.07 $14.89 2.09
2016-09-30 29.34 $15.19 1.93
2016-06-30 32.16 $15.17 2.12
2016-03-31 29.60 $15.77 1.88
2015-09-30 34.98 $16.30 2.15
2015-06-30 36.50 $16.63 2.20
2014-06-30 37.95 $16.88 2.25
2013-06-30 35.49 $17.03 2.08
2012-06-30 25.15 $17.62 1.43
2012-03-31 24.65 $17.83 1.38
2011-12-31 23.24 $17.94 1.30
2011-09-30 20.86 $17.40 1.20
2011-06-30 25.55 $17.02 1.50
2011-03-31 21.65 $16.45 1.32
2010-12-31 19.81 $15.82 1.25
2010-09-30 20.44 $15.82 1.29
2010-06-30 18.48 $15.87 1.16
2010-03-31 22.15 $15.83 1.40
2009-12-31 23.29 $15.62 1.49
2009-09-30 21.91 $17.04 1.29
2009-06-30 17.49 $17.42 1.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $117.121B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Novo Nordisk (NVO) Denmark $550.665B 45.36
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AbbVie (ABBV) United States $294.653B 14.98
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Innoviva (INVA) United States $0.945B 6.67